https://www.selleckchem.com/pr....oducts/Paclitaxel(Ta
edited centres has not been completely considered and annuity payment and broader perspective in cost considerations are far from being put in place. These recommendations should be considered for future PR negotiations to pursue rational resource allocation and deal with budget constraints. Expert recommendations for ATMPs PR were partially applied the role of outcome-based MEAs has increased and the selection process of the centres authorized to use these treatments has been enhanced; additional funding for ATMPs m
Like
Comment
Share
